Approved from age 2, but limited to specific genetic disorders (e.g., biallelic POMC, LEPR, Bardet-Biedl syndrome) [108], and may be used in this age range (genotype-restricted). This evidence concerns the gene LEPR and Bardet-Biedl syndrome.